Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q3 2026
Amphastar Pharmaceuticals (AMPH) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Amphastar Pharmaceuticals (AMPH) reported revenue of $208M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +13% from the quarter before. Operating margin was 24.5%, net earnings $37.8M (18.2% of revenue).
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $208M | +13% | +8% |
| Gross profit | $99.6M | +7% | +1% |
| Operating profit | $50.8M | +28% | +101% |
| Net earnings | $37.8M | +24% | +118% |
| Operating cash flow | $43.3M | -16% | -18% |
| Free cash flow | $33.4M | -22% | -29% |
What changed
Revenue was $207.6M in Q3 2026, up 8% year over year and up 13% from the previous quarter.
Gross margin was 48.0%, down 3.4 points from Q3 2025. Operating profit was $50.8M, a 24.5% margin (up 11.3 points year over year). Of the extra revenue versus Q3 2025, 161% reached operating profit, above the 13% margin then. Operating expenses fell 33% while revenue rose 8%. Net earnings were $37.8M, up 118% year over year. The effective tax rate was 23.0%.
Operating cash flow was $43.3M (down 18% year over year), 115% of net earnings. Non-cash charges added back $15.6M of depreciation and amortization and $7.0M of share-based compensation. Working capital and other items used $17.1M. Capital expenditures of $9.9M left free cash flow of $33.4M.
Questions
What was Amphastar Pharmaceuticals' revenue in the third quarter 2026?
Amphastar Pharmaceuticals (AMPH) reported revenue of $208M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +13% from the quarter before.
Was Amphastar Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $50.8M (24.5% of revenue) and net earnings $37.8M.